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Abstract 
The therapeutic potential of hyperbranched polymers targeted to prostate cancer and loaded with doxorubicin 
was investigated. Polyethylene glycol hyperbranched polymers were synthesised via RAFT polymerisation to feature 
glutamate urea targeting ligands for PSMA on the periphery. The chemotherapeutic, doxorubicin, was attached to the 
hyperbranched polymers through hydrazone formation, which allowed controlled release of the drug from the 
polymers in in vitro endosomal conditions, with 90 % release of the drug over 36 hours. The polymers were able to 
target to PSMA-expressing prostate cancer cells in vitro, and demonstrated comparable cytotoxicity to free doxorubicin. 
The ability of the hyperbranched polymers to specifically facilitate transport of loaded doxorubicin into the cells was 
confirmed using live cell confocal imaging, which demonstrated that the drug was able to travel with the polymer into 
cells by receptor mediated internalisation, and subsequently be released into the nucleus following hydrazone 
degradation. Finally, the ability of the complex to induce a therapeutic effect on prostate cancer cells was investigated 
through a long term tumour regression study, which confirmed that the DOX-loaded polymers were able to significantly 
reduce the volume of subcutaneous prostate tumours in vivo in comparison to free doxorubicin and a polymer control, 
with no adverse toxicity to the animals. This work therefore demonstrates the potential of a hyperbranched polymer 
system to be utilised for prostate cancer theranostics.   
Introduction 
Prostate cancer remains a worldwide health concern, with over 600,000 cases and 200,000 men dying annually 
around the world.
1, 2
 Early stage prostate cancer typically has favourable outcomes, with a high rate of successful 
treatment and promising 5-year survival rates. However, late-stage prostate cancer has a significantly reduced 
prognosis due to a combination of many factors, including low specificity treatments in the clinic, a limited ability to 
diagnose in the early stages and complications related to advanced, metastatic occurrences of the disease, where the 
cancer has spread from the original disease site to other areas of the body.
3-8
 The ability to efficiently target disease 
sites while simultaneously delivering treatment and diagnostic capabilities is the next crucial step towards improving on 
these outcomes. 
Current treatments in the clinic are predominantly systemically administered chemotherapeutic drugs, external 
radiation and surgery.
9
 While these treatments are successful in some cases, they are typically ineffective once the 
cancer reaches a metastatic castrate resistant stage. In the case of chemotherapeutic drugs that are delivered 
systemically, the toxicity to normal rapidly dividing cells such as red blood cells and immune cells is a significant 
problem.
10
 Additionally, the poor bioavailability of most chemotherapeutics imparts a significant limitation on the dose 
that can be delivered to the site of interest, and can negatively impact on the efficacy of the treatment through reduced 
tumour site localisation.
11, 12
 However, the advantage of chemotherapy is that it is able to distribute throughout the 
body to treat tumours in multiple locations, whereas surgical and radiation approaches are confined to treating one 
area. Therefore, while both surgery and radiation can be highly effective for singular, large tumour masses, they are 
extremely inefficient techniques for treating metastatic cancer, and thus there remains a lack of treatment options that 
are both highly specific and effective for multiple tumour masses.
13
 In order to overcome the current limitations, 
significant research effort in the area of nanotechnology is focused on improving this quality of treatment through 
achieving an increase in the dose localisation to tumour sites, in addition to reducing non-specific systemic toxicity. 
It is proposed that this can be achieved through promoting the selective accumulation of a carrier molecule 
specifically within tumour sites. It is well known that the vasculature surrounding a tumour is typically severely 
compromised as a result of the rapidly dividing nature of cancer cells, a phenomenon which has been exploited in 
nanomedicine through the Enhanced Permeation and Retention effect (EPR effect).
14
 In addition to the leaky blood 
vessels,  poor lymphatic drainage in the area contributes to enhanced retention of circulating particles.
15
 This has led to 
the development of nanoparticle drug delivery carriers that can achieve preferential accumulation within tumour sites, 
and thereby have the ability to deliver drugs in more a targeted manner. This can additionally be improved upon 
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of specific antigenic interactions.
16
 The addition of an active targeting ligand provides the drug delivery carrier with the 
capability for tumour cell uptake through the recognition of specific cell-surface receptors for surface binding.
17
 This 
can translate into increased control over the final accumulation and biodistribution of the carrier following systemic 
injection. Both passively and actively targeted particles are likely to accumulate in the tumour site through the EPR 
effect, however, following localisation within the interstitial space, particles with an appropriate active targeting ligand 
will then recognise their receptor target, bind, and be retained within the tumour environment. Additionally, if the 
target receptor is internalising, this is then followed by internalisation into the cells.
18
 This is an especially important 
consideration for drugs that act intracellularly, indicating that internalisation is mandatory for an efficient therapeutic 
effect, such as in gene delivery.  
Utilising a biocompatible ‘stealth’ polymer carrier is an approach towards this that has been widely 
investigated.
19-22
 The construction of biocompatible nanoparticles with a PEG coating for example, provides a carrier 
vehicle with long circulation times in vivo through both an increased size, and the ability to evade clearance from the 
bloodstream by the mononuclear phagocyte system (MPS).
23, 24
 There exist many examples in the literature in which 
nanoparticles have demonstrated their versatility through functionalisation with various components for imaging, 
targeting and drug delivery, such as nanoparticles featuring active targeting ligands and encapsulating therapeutic 
drugs.
25, 26
 A further advantage of utilising a polymer based system is that the circulation times and clearance 
mechanisms of the nanoparticles are able to be tuned through manipulation of the properties of the carrier material, 
for example to allow long-term sustained released through controlled erosion, or capsule degradation at the active site 
through the use of biodegradable monomers.
27-30
   
The other important aspect that must be considered is how the drug will be incorporated into the nanoparticle. 
Several early examples of drug delivery nanoparticles feature the drug cargo encapsulated within a central cavity, such 
as within a liposome or a vesicle.
31
 However, this method does not allow for precise control over the encapsulation and 
release of the drug, and physically encapsulated drugs can also be prone to leakage from the carrier while in 
circulation.
32-35
 An alternative design is to tether the drug to the nanoparticle through a covalent linkage. While 
attachment of drugs to nanoparticle carriers through covalent chemistry requires more sophisticated synthetic 
requirements, the resultant system will typically be more stable to unwanted burst release of the drug, can facilitate a 
higher loading efficiency, and provides additional control over both the rate of the release and the site of drug release 
in vivo.
36-38
 The release of the drug from the nanoparticle can be triggered through degradation of the covalent 
attachment, which can be achieved through a range of biological environments present in the target location. Typical in 
vivo conditions that are exploited for this purpose are the acidic environment of a tumour, the acidity of the endosome, 
and the enzymatic environment of the cell cytosol.
39-43
 An actively-targeted nanoparticle will be localised within 
endosomes following endocytosis, which have pH ranges of ~4.5 to 6.5, providing opportunity for stimuli-responsive 
release through acid-labile linkages.
44
 There are several covalent linkages that are commonly used for this purpose, 
including an acetal, ester or a hydrazone bond, which when used in conjunction with a targeted nanoparticle towards 
these environments will allow for specific release of the drug payload in the extracellular or vesicular sites.
45-47
  
Our group has previously described a theranostic based on a hyperbranched polymer platform with targeting 
capabilities for prostate cancer through a small molecule ligand for Prostate Specific Membrane Antigen (PSMA).
48
 
PSMA has been identified as a specific cell-surface receptor that is overexpressed on many prostate cancers, as well as 
on lymph node and bone metastases of the disease, but with low levels detected on normal prostate tissues. Therefore, 
PSMA is considered a promising candidate for the specific delivery of nanoparticles to prostate cancer, with PSMA-
targeted nanoparticles in clinical trials.  Our previous work demonstrated preliminary evidence of stimuli-responsive 
drug delivery capabilities through the inclusion of a hydrazide monomer within the backbone of the hyperbranched 
polymer, which allowed for attachment of a model fluorescent drug through formation of hydrazone bonds. Here, we 
present further work on this system by exploring the targeted, stimuli-responsive controlled release of a 
chemotherapeutic through more extensive in vitro and in vivo characterisation, with efficacy of the nanomedicine as a 
therapeutic demonstrated in tumour regression studies in mice. The overall approach is described in Scheme 1. 
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Experimental 
Characterisation Methods 
All NMR experiments were undertaken on a Bruker Avance 500 high-resolution NMR spectrometer. 
1
H NMR 
spectra were collected for 128 scans. All 
1
H diffusion spectra were recorded at 500 MHz at 95% gradient, ambient 
temperature, and 256 scans. 
In vitro flow cytometry was performed on an Accuri C6 Flow Cytometer (BD Bioscience, San Jose, CA) using the 
640 nm laser collecting through the 675/25 filter (Cy5).  
In vitro microscopy images were acquired on a Carl Zeiss LSM 710 confocal laser scanning microscope.  
In vivo optical imaging experiments were performed on an In Vivo MS FX Pro instrument (now supplied by Bruker 
Corporation). Cy5 images were collected with a 630 ± 10 nm excitation and 700 nm ± 17.5 nm emission filter set (f- stop 
2.80, 2 × 2 binning, 190 mm FOV, 10 sec exposure time). DsRed fluorescence images were collected with a 550 ± 10 nm 
excitation and 600 nm ± 17.5 nm emission filter set (f-stop 2.80, 2 × 2 binning, 120 mm FOV, 20 s exposure time). To 
provide anatomical context, fluorescence images were co-registered with an X-ray image (f-stop 2.80, 0.2 mm 
aluminium filter, 190 mm FOV, 30 sec acquisition time). All images were batch exported as 16-bit TIFF images and 
image processing was completed using Image-J (National Institutes of Health). Fluorescence images were false coloured 
and overlaid onto X-ray images. 
Hyperbranched polymer synthesis 
The hyperbranched polymers used in this study were synthesised as previously described.
48
 For this study they 
were labelled HBP-GU (glutamate urea targeted) or HBP (untargeted control).   
Doxorubicin attachment to hyperbranched polymer (HBP-GU-DOX) 
HBP-GU (20 mg, 5.7 x 10
-2
 mmol) was dissolved in 100 µL dry methanol in a glass vial equipped with a stirrer bar. 
DOX.HCl (1.69 mg, 2.92 x 10
-3
 mmol, 0.25 eq’ to hydrazides) was added and the reaction stirred overnight at 40 
o
C. The 
reaction was purified by precipitation into hexane/diethyl ether 3 times, followed by size exclusion purification using a 
Scheme 1. The overall reaction scheme for the formation of HBP-GU-DOX. The base polymer carrier was synthesised by RAFT 
polymerisation, followed by attachment of doxorubicin through hydrazone formation. 
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= 480 nm, em = 580 nm).   
In vitro buffer release study 
Phosphate buffer solutions at pH 5.5 and 7.4 were used to simulate endosomal and physiological pH. A 
calibration curve of DOX.HCl was prepared by measuring ten concentrations in a 48 well plate in pH 7.4 phosphate 
buffer. The excitation and emission wavelengths were 480 nm and 580 nm respectively. The samples were measured in 
a Tecan plate reader at a depth of 19 mm with 10 flashes and an integration time of 20 µs.  
The following release study was performed in triplicate to account for statistical variation between subsets. 1.0 
mg of HBP-GU-DOX was dissolved in 1 mL pH 7.4 phosphate buffer. The dissolved polymer was added into a 3.5 kDa 
MWC dialysis cassette, and placed into a sealed glass apparatus containing 100 mL of either pH 7.4 or 5.5 phosphate 
buffer. All samples were stirred at 37 
o
C for 48 hours. Aliquots of the dialysis buffer (1 mL) were removed at various 
time points, replacing with fresh buffer. The samples were measured on the plate reader using the same settings as the 
standards. 
In vitro cell uptake study  
Studies were undertaken to analyse the uptake and stability of the HBP-DOX conjugates in cell growth medium. 
Human prostate cancer LNCaP cells were seeded into 24 well plates (4.0 x 10
4
 cells per well) and incubated overnight 
with RPMI(Life Technologies, Mulgrave, Vic, Aust) containing 10 % foetal bovine serum (FBS; Moregate, Brisbane, Aust) 
at 37 
o
C with 5% CO2. The incubation medium was removed and 500 µL of polymer-containing medium at various 
concentrations was added to each well. The cells were incubated at 37
 o
C for 30 mins, 2 hrs or 4 hrs. Following 
incubation the polymer solution was removed and the cells were washed with fresh RPMI three times. Cells were 
detached from the wells using trypsin-EDTA and transferred to Eppendorf tubes containing 1 drop of FBS. The cells 
were centrifuged into pellets, resuspended in PBS and analysed by flow cytometry.  
In vitro cytotoxicity  
For cytotoxicity measurements, LNCaP prostate tumour cells were seeded into 96 well plates at a density of 1.5 x 
10
3
 cells per well in 100 µL of RPMI. The cells were allowed to adhere in growth media overnight at 37 
o
C. The cell 
media were discarded and replaced with fresh media (100 µL) containing either free doxorubicin, HBP-GU or HBP-GU-
DOX at eight different concentrations, each in triplicate. The cells were incubated for either 24 or 48 hours; these 
incubation times were devised based on the release profile of the DOX from the hyperbranched polymers. Cell viability 
was then assessed by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) 
assay (CellTiter 96 AQuesous One Solution Cell Proliferation Assay; Promega) following provided manufacturers 
methods. Briefly, wells were washed once with 200 µL growth media before addition of 100 µL of growth media 
containing 20% (v/v) MTS assay reagent. Plates were incubated for 30 mins at 37 °C and absorbance at 490 nm of each 
well was measured. Absorbance readings of blank wells (no cells) were subtracted from all readings and then values 
were normalised to cells grown in the absence of test compounds. Cell viabilities were calculated and statistical 
significance calculated through unpaired t-tests (Significance P<0.05).  
In vitro confocal microscopy 
Live cell confocal microscopy was performed on the HBP-GU, HBP-GU-DOX and free DOX to further quantify 
uptake into LNCaP tumour cells in real-time. In preparation for imaging, a suspension of LNCaP cells was plated into 
Ibidi
tm
 coverslip-bottom µ-dishes (0.5 mL per dish) supplemented with 2 mL of complete RPMI media, returned to the 
incubator and left overnight. Imaging of intracellular distribution and doxorubicin release was performed on a Zeiss 710 
inverted laser scanning confocal microscope equipped with a 40x water immersion lens in addition to Argon and 
Helium-Neon lasers. Prior to imaging, cellular morphology and health was assessed using brightfield imaging. 40 µL of a 
0.25 µM solution of HBP-GU or HBP-GU-DOX or 40 µL of a 1.21 µM free DOX was added to the media and the cells were 
monitored over time. Example cells were selected, the field of view and zoom factor altered and the resolution 
optimised using the inbuilt function in the Zeiss software. As the control polymer and DOX concentrations were 
matched to the targeted DOX loaded polymer, channel settings such as gain were determined from DOX and Polymer 
alone samples. Images were post-processed using Zen Lite 2012 (Blue Edition) (Carl Zeiss Microscopy GmbH), being 
smoothed with a Gaussian Filter (Sigma value of 0.9 in both the X & Y directions), prior to being exporteds as TIF files 
with no compression. Fluorescence intensity was extracted using the Zen Lite software from the raw data files using the 
Regions of Interest (ROI) tool to select cellular features and the measure capabilities for statistical analysis. 
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In vivo imaging 
All studies were in accordance with guidelines of the Animal Ethics Committee of The University of 
Queensland (UQ), and Australian Code for the Care and Use of Animals for Scientific Purposes. Studies were 
undertaken to quantify the in vivo behaviour of the doxorubicin-loaded glutamate urea-targeted polymer, 
HBP-GU-DOX. A male nu/nu mice was implanted subcutaneously with 2 × 10
6 
PSMA positive PC3-PIP cells on 
the right flank. The imaging experiment was performed 11 days after tumour cell injection. HBP-GU-DOX was 
diluted in PBS to 5 mg mL−
1
, and 200 μL was injected into the mouse via the tail vein. Fluorescence and XRay 
images were acquired using an In Vivo MS FX Pro imaging station. Mice were anaesthetised with 2 % isoflurane 
during all procedures. 
In vivo tumour regression study 
13 male nu/nu mice were injected with LNCaP cells in the left flank to induce subcutaneous tumours. The mice 
were split into 5 groups, 3 x control (saline), 2 x control (HBP-GU), 3 x free DOX, 2 x HBP-DOX and 3 x HBP-GU-DOX. 
HBP-GU-DOX, HBP-DOX and free DOX was administered at a DOX concentration of 4.5 mg/kg, with the control polymer 
equal to the HBP-GU-DOX polymer concentration. After the tumours reached approximately 75 mm
2
 in volume (tumour 
volume = ½ (length × width 
2
)
49
, the mice received the appropriate treatment intravenously on days 1, 3, 7, 11 and 18, 
except for the HBP-DOX group which was dosed on day 14 instead of day 11.
50
 The mice were monitored, including 
body mass and tumour volume measurements over a 28 day period. At the end of the 28 day period, or once tumours 
reach 1000 mm
3
 in size, the mice were culled and their organs and tumour removed and imaged in an MSFX Pro to 
visualise polymer accumulation within the tissues (ESI, Figure S4). 
Results and Discussion 
Drug attachment and characterisation 
The aim of this work was to investigate the efficacy of a doxorubicin-loaded hyperbranched polymer targeted to 
prostate cancer, through the use of a small molecule glutamate urea as previously described by our group.
48
 
Doxorubicin was chosen as the chemotherapeutic for this study, as it is a well-documented anti-cancer agent that is 
effective on some prostate cancer cells, and furthermore it has the ability to act as a fluorophore, enabling efficient 
characterisation in vitro.
51, 52
 Additionally, doxorubicin inherently features a sterically-unhindered ketone functionality 
suitable for hydrazone formation with a hydrazide, enabling it to be used in this study without further modification.
53, 54
  
Refluxing the hyperbranched polymers featuring hydrazide moieties in methanol overnight with DOX.HCl (0.25 
equivalents of DOX to hydrazides) resulted in a high percentage of functionalisation (94 %). This demonstrates close to 
quantitative attachment of DOX to the hydrazides within the polymer backbone, and therefore that the hyperbranched 
system can successfully facilitate drug loading in high yield. As the DOX-loaded polymers were to be utilised for imaging 
studies, the DOX was reacted at 0.25 equivalents to hydrazide in order to ensure the final polymers had approximately 
equal emissions of both DOX and Cy5. Following the hydrazone formation with the DOX, the HBP was purified through 
size exclusion to ensure no free DOX remained in the system. The DOX concentration per polymer was subsequently 
characterised by quantitative 
1
H NMR (the representative peaks b,c,d,h are highlighted in Figure 1), which allowed the 
calculation of an average of 1.1 DOX molecules per arm of the hyperbranched polymer. By utilising SEC with multiangle 
laser light scattering (MALLS) to quantify the absolute molecular weight of the polymers, the total number of arms 
within each hyperbranched polymer was calculated to be an average of 4.6, and therefore the total number of DOX 
molecules per hyperbranched polymer was calculated to be 5.06. This was confirmed through UV-Vis spectroscopy (480 
nm), utilising a standard curve of free DOX, which calculated a total of 4.62 DOX per polymer. The total number of DOX 
molecules per polymer was taken as an average of both techniques: 4.84 DOX molecules per HBP. The diameter of the 
hyperbranched polymers was measured by DLS, and found to be 6.2 nm.  
Table 1. Summary of the physical and chemical properties of the final DOX-loaded and PSMA-targeted hyperbranched polymer (HBP-
GU-DOX) 
Mn (
1
H NMR) Mn (ĐM) SEC-
MALLS 
# hydrazides / 
polymer 
Theoretical # DOX
*
 # DOX (
1
H NMR) # DOX (UV-Vis) Dh
^ 
8.5 kDa 39 kDa (1.7) 20.42 5.11 5.06 4.62 6.2nm 
* Theoretical DOX calculated based on feed ratio and 100 % coupling efficiency. ^Size measurement calculated from HBP-GU. 
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 In vitro characterisation of the polymer-drug conjugate 
Following the attachment, purification and characterisation of the DOX loading onto the hyperbranched 
polymers, an initial in vitro buffer release experiment was conducted to determine the stability of the conjugates, as 
well as their release kinetics under physiologically relevant conditions of pH. The HBP-GU- DOX was dialysed in either 
pH 5.5 (endosome conditions) or7.4 (serum conditions) phosphate buffer at 37 
o
C for 48 hours, during which time the 
buffer was measured at various time points for the DOX concentration, which is indicative of release from the polymer 
system. Utilising standards of free DOX, the data was able to be transformed to represent the percentage release of the 
initial total DOX from the HBPs over time. As previously shown by many researchers, the DOX-conjugated polymer 
demonstrated remarkable stability at neutral pH, with less than 10 % release at pH 7.4 over 48 hours.
46, 55
 However, 
during this same timeframe at an acidic pH of 5.5, such as in the endosome, 90 % of the initial conjugated DOX was able 
to be released in a controlled manner, with no burst release, and a half-life of 12 hours (Figure 2A). This experiment 
therefore provided preliminary confirmation of the viability of the HBPs for controlled, stimuli-responsive drug delivery. 
Following the initial release experiments, the next investigation probed the reproducibility of the in vitro release 
kinetics in a cellular environment. This was done through both in vitro uptake studies of the HBPs into LNCaP prostate 
cancer cells, as well as in vitro cytotoxicity assays over extended time points. Initially, both DOX-loaded and unloaded 
glutamate urea targeted HBPs were incubated with LNCaP prostate cancer cells and their uptake quantified using flow 
cytometry. HBP-GU-DOX, HBP-GU and an additional control untargeted polymer (HBP) were used at concentrations 
ranging between 0.025 µM to 0.2 µM, over three time points: 30 mins, 2 hours and 4 hours. After incubation with the 
polymer solutions, the cells were washed and resuspended in PBS for flow cytometry analysis. The ability of the 
glutamate urea targeted polymers to selectively bind to PSMA+ cells was confirmed, with a clear trend of increasing Cy5 
signal, and thus polymer uptake, into the LNCaP cells with increasing concentration and incubation time. As a control, 
untargeted HBP was also tested, and demonstrated significantly lower uptake into the LNCaP cells, confirming that 
uptake is likely due to the inclusion of the active targeting ligand. Importantly, the HBP-GU-DOX did not behave 
significantly differently to the HBP-GU, suggesting that there is no detrimental effect on polymer uptake with the 
inclusion of the hydrophobic drug (Figure 2B). Analysis of the percentage of cells that were alive during the flow 
cytometry experiment did not show a significant cytotoxic effect on the cells over the short time frame tested, which is 
consistent with the timeframe of DOX release as described by the buffer release study (Figure S3, ESI). 
Figure 1.  
1
H 1D DOSY NMR spectra of the HBP-GU-DOX confirming the successful hydrazone formation with the drug. 
Resonances used for quantification of DOX attachment are highlighted (b, c, d and h). 
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Following the confirmation of selective uptake into the tumour cells by the glutamate urea targeting ligand, 
cytotoxicity studies were completed to quantify the toxicity of both the unloaded HBP-GU and the DOX-loaded HBP-GU 
in comparison to free DOX. If the DOX is able to be released in the endosome through hydrolysis of the hydrazone bond 
following internalisation, the resultant free DOX should then be able to impart toxicity on the cell, triggering apoptosis. 
Therefore, if the HBP is successful in delivering DOX to the endosome within the cells, we hypothesised that the 
cytotoxicity should be similar to that of free DOX beyond the timeframe of DOX release. In order to quantify this, LNCaP 
cells were incubated with their respective treatment at eight different concentrations over both 24 and 48 hours. The 
cell viability was analysed through an MTS assay, with untreated cells utilised as a baseline reading for cell viability over 
the experiment. The cytotoxicity of each polymer sample was quantified as a percentage of viable cells from a ratio of 
the untreated cells. 
As expected, over the initial 24 hour period, both the HBP-DOX and free DOX were able to reduce cell viability to 
65 % and 45 % respectively for the highest concentrations of DOX, suggesting that the DOX was successfully released 
from the polymer carrier and able to induce apoptosis within the cell (Figure 3A). This conclusion was supported by the 
control HBP demonstrating no toxicity over the same concentration range and time frame (90 % cell viability for the 
highest concentration). This result is consistent with the buffer release study, where at 24 hours almost 80 % of the 
DOX had been released from the HBP-GU-DOX. By 48 hours, the control HBP remains nontoxic to the cells, with 90 % 
cell viability at the highest concentrations of polymer, while the cytotoxic effect from the DOX is increased in both the 
HBP-DOX and free DOX samples (Figure 3B) to 30 % and 20 % cell viability respectively at the highest concentrations of 
DOX. This is likely due to a combination of further release of the DOX from the HBP through continued hydrolysis of the 
hydrazone bond, in addition to the prolonged exposure of the cells to the DOX during the additional 24 hour period.   
Figure 2. Data showing A) the in vitro buffer release profile of DOX in simulated in vivo conditions, and B) uptake of the HBPs in 
LNCaP prostate cancer cells demonstrating increased uptake over concentration and time when an active targeting ligand is 
featured on the surface of the nanoparticle. Data represents mean ± SD (n = 3).
Figure 3.  The cytotoxicity of the HBP, free DOX and the HBP-DOX conjugate on LNCaP tumour cells at A) 24 hours and B) 48 hours as 
quantified by an MTS assay. Data represents mean ± SD (n = 3), statistical significance calculated through unpaired t-tests 
(Significance P<0.05).
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The ability for the hyperbranched polymers to deliver the DOX into the cells through receptor-mediated 
internalisation was further characterised through live cell confocal microscopy. The rationale behind this experiment 
was to analyse the mechanism of DOX internalisation into cells when the DOX was tethered to a polymer carrier, as 
compared to free DOX in solution. In order to investigate this, the internalisation of HBP-GU-DOX, free DOX and HBP-
GU as a polymer control were qualitatively analysed in live LNCaP cells. Immediately prior to imaging, the respective 
treatment (diluted in cell culture media) was added on top of the cell monolayer, after which images were acquired at 
regular time points utilising the appropriate emission filters. The internalisation behaviour and cellular distribution of 
the control HBP-GU and the free DOX were used as the expected baseline behaviour for the internalisation of a polymer 
and small molecule chemotherapeutic respectively, for the comparison of the behaviour of the polymer DOX conjugate.    
The HBP-GU and free DOX indeed demonstrated different behaviours in vitro. Figure 4 shows representative live 
cell confocal micrographs taken at 2 hours post exposure to the respective treatment. It can be seen in Figure 4 (A & B) 
that the DOX was successfully able to travel into the LNCaP cells over time. However, the images suggest that the DOX 
relied on passive mechanisms of diffusion into the cells, which resulted in diffuse cytoplasmic staining. In comparison, 
Figure 4 (C–F) demonstrates that the HBP-GU was also successfully able to transport into the cells, however, the 
polymer displays more sophisticated methods of internalisation, suggesting receptor-mediated transport. This is 
illustrated by trafficking along the focal adhesion and the combination of punctate and filamentous staining within the 
cellular milieu, which is indicative of vesicular transport. Furthermore, it can be seen that after 2 hours, the localisation 
of fluorescent signal within the cells is different for the DOX and HBP-GU. After 2 hours, the free DOX shows significant 
fluorescence within the cell nuclei. This is expected behaviour, as the mechanism of action for DOX is to bind to DNA, 
and therefore, following passive diffusion into the cell cytoplasm, the DOX was clearly able to accumulate within the 
nucleus. This was not observed for the HBP-GU; after 2 hours, the polymer is still retained within vesicles in the cells, as 
demonstrated by specific vesicular staining within the cytoplasm, further supporting receptor-mediated endocytosis as 
the route of cell internalisation. 
The images acquired of the HBP-GU-DOX in vitro demonstrate behaviour that is consistent with that of the 
control HBP-GU (Error! Reference source not found.). It can be seen that the staining and localisation of the Cy5 
fluorescence within the cells is comparable to that of the HBP-GU, confirming that the HBP-GU-DOX is also able to 
transport into the cells through receptor- mediated internalisation. Of particular note, the staining of DOX within the 
Figure 4. Confocal micrographs of DOX and HBP-GU distributions in live LNcaP prostate cancer cells at 2 hours post exposure. A) DOX 
staining with brightfield overlay, features indicated in the fluorescence only image of the same cell, B) include nuclear staining 
(asterisk), diffuse cytoplasmic staining (arrowhead) and an example of a region with much lower than background fluorescence in 
the cellular milieu (oval). Examples of cells showing uptake of GU-HBP are given in (C & D), a brightfield overlay being presented in 
C). Features labelled by the material include focal adhesions (arrows) and a combination of vesicular and filamentous structures (an 
example is highlighted by a rectangle). Higher magnification image from towards the basal surface of an example cell displaying 
these features is given with a brightfield overlay e) and Cy5 fluorescence alone F) illustrating vesicular structures (rectangle) and 
focal adhesion staining (arrows) in greater detail (scale bar in E & F is 5 µm). Where applicable, nuclei are marked (N). 
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cells displays significantly different behaviour in these images. Rather than diffuse cytoplasmic staining, the DOX is 
showing obvious staining of the focal adhesions and highlighting vesicular and filamentous structures in the cellular 
milieu, mimicking the staining patterns for the HBP-GU, and thus confirming the ability of the polymers to facilitate 
specific DOX transport into the cells. In addition to the vesicular localisation of the DOX within the cells, by 2 hours post 
exposure, the DOX is beginning to demonstrate some characteristic nuclear staining. From the buffer release study, in 
simulated endosomal conditions, the HBP-GU-DOX demonstrated slow and controlled release of the DOX from the 
polymers over approximately a 30 hour period, with approximately 30 % released over the first 120 minutes. It is thus 
expected to see the DOX remaining bound to the polymer initially within the cells, as seen in the localisation of the DOX 
within vesicles, with evidence of some release by the 2 hour images. Thus, these images support the hypothesis that 
following internalisation into the endosome, the DOX is able to be released from the polymer carrier through hydrolysis 
of the hydrazone linkage, exit the endosome and travel into the nucleus.  
 
In order to further understand the different behaviours of each sample within the cells, and to confirm the 
qualitative analysis based on the confocal images, the localisation of the fluorescent signal within the cells was analysed 
quantitatively through ROI analysis (Figure 6). In the same 2 hour images, regions of interest were drawn within various 
compartments within the cells and normalised to the maximum fluorescence intensity found within the entire image. 
The ROI analysis was able to quantitatively confirm the difference in intracellular localisation between the free DOX and 
the DOX-loaded HBP. 
For free DOX, significant signal is located within the nucleus after 2 hours, with minimal localisation within the 
cytoplasm and vesicles. However, the DOX signal for the HBP-GU-DOX demonstrates predominant localisation within 
vesicles and the cytoplasm, with significantly less fluorescence located within the nucleus. The Cy5 fluorescence does 
not appear to vary significantly between the DOX-loaded and unloaded polymers, confirming that the inclusion of the 
DOX within the polymers does not have a significant effect on the method of transport into the cells.  Additionally, the 
ROI analysis confirms that the predominant source of Cy5 fluorescence is within vesicles, focal adhesions and the 
cytoplasm, with negligible signal in the nucleus. However, by the 2 hour images, the HBP-GU-DOX shows higher DOX 
signal in the nucleus than Cy5 signal, which supports the hypothesis of DOX release following internalisation and 
localisation within vesicles, triggering degradation of the hydrazone linkages. All of this information taken together 
suggests that the targeted polymer enhances rapid accumulation of the nanomedicine within the cell through receptor-
mediated endocytosis, with subsequent release of the DOX which then migrates to the nucleus of the cell. 
In vivo tumour regression study of polymer-drug conjugate 
Figure 5. Confocal micrographs of HBP-GU-DOX in live LNcaP prostate cancer cells at 2 hours post exposure. A) dual-coloured image 
with brightfield overlay, B) combined doxorubicin and Cy5 fluorescence, C) doxorubicin channel, D) Cy5 channel. Focal adhesion 
staining is labelled with an arrow, vesicular structures a rectangle, filamentous features with an oval and nuclear fluorescence is 
indicated (asterisk). Nuclei are marked (N). 
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The extensive in vitro characterisation described above confirms the selective and stimuli-responsive delivery of 
doxorubicin to PSMA-positive cells through the glutamate urea targeted HBPs. Following this, the ability for the HBP to 
impart a therapeutic effect on tumour cells in animal models was investigated. The intent behind developing targeted, 
nanoparticle drug delivery carriers is in the specificity and increased efficiency of treatment; it is desired that the 
nanoparticles are able to deliver a therapeutically effective dose to the tumour site with minimal non-specific toxicity 
elsewhere in the body. 
Prior to conducting an in vivo tumour regression study to assess the suitability of the HBP-GU-DOX for this 
purpose, an in vivo imaging study was performed in order to confirm that the in vivo behaviour of the targeted DOX-
loaded polymer was not significantly affected by the presence of the hydrophobic drug within the polymer core. It was 
hypothesised that there would be no significant effect due to both the relatively low incorporation of the drug within 
the polymer (6% w/w), and the branched, hydrophillic nature of the HBPs. To compare with previous in vivo studies of 
the polymer without drug, a male nude mouse was implanted with a subcutaneous PC3-PIP (PSMA-expressing) tumour. 
The tumour was allowed to grow for 11 days, and then HBP-GU-DOX was injected via the tail vein and fluorescence 
images acquired at 24 hours post-injection. The resultant images (Figure 7) confirm behaviour comparable to that of 
the unloaded HBP-GU as in previous work.
48
 By 24 hours there is significant accumulation of the polymer within the 
subcutaneous tumour, as well as signal in the region of the kidneys, indicating clearance through this route. The size 
cut-off for renal clearance is approximately 6 nm, and therefore it would not be expected to see clearance through this 
route if any significant micellisation or aggregation were occurring.
56, 57
 Any materials that are larger than 8 nm, and 
therefore unable to filter through the kidneys, are expected to be cleared through hepatic routes. There is no polymer 
signal in the region of the liver, and therefore it can be concluded that the drug-loaded polymers are stable in vivo.
56
 
Following confirmation of the consistent in vivo behaviour between drug-loaded and non-loaded polymers, the 
ability of the HBP-GU-DOX to impart a therapeutic effect was investigated through a tumour regression study. 13 nude 
mice had subcutaneous LNCaP tumours induced on the left flank. After the tumours had grown over a 6 week period, 
the mice were divided into five treatment groups: saline control, HBP-GU control, HBP-DOX, HBP-GU-DOX and free 
DOX. The mice received intravenous injections of the relevant treatment on pre-determined days over a 28 day period 
(Figure 8). Throughout the 28 days, the health of each mouse was monitored through their body mass, and the size of 
the tumour measured through calliper measurements. The tumour volumes were calculated using a standard volume 
formula as previously reported (tumour volume = ½ (length × width 
2
). At the end of the 28 days, or once tumour 
volumes reached over 1000cm
3
, the mice were culled and the tumours measured ex vivo to confirm the accuracy of the 
in vivo measurements. The resultant data was transformed into a percentage of the original body mass and tumour 
volume for comparison between the five experimental groups. It can be seen in Figure 8B that as expected, the 
tumours in the saline control group continued to grow substantially over the experimental period. Likewise, the control 
polymer group, HBP-GU, did not have a therapeutic effect on the subcutaneous tumours, with the tumours from both 
control groups growing to approximately 300 % of their original volume. The untargeted HBP-DOX was also 
unsuccessful at inducing a therapeutic effect in the animals; while the growth of the tumours was not as significant as in 
the two control groups, perhaps indicating some arrest of tumour growth, by the end of the study the tumours were at 
200 % of their original volume. 
Figure 6. The average fluorescence intensity within various cellular compartments based on ROI analysis of the confocal micrographs 
at 2 hours post exposure. Data represents mean ± SD (n = 4). 
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It can be seen that the control polymer was not toxic to the animals, as their body mass did not vary significantly 
over time. This was the expected result, as the in vitro cytotoxicity suggested that the control polymer was not toxic to 
the LNCaP cells, and PEG is well known to be biocompatible.
19, 22
 The body mass of the animals in the saline control 
group and HBP-DOX group only suffered slightly, with the animals finishing at 92 - 93 % off their original mass at the 
end of the study, which is likely due to the larger tumours in these two treatment groups in comparison to the other 
three groups. The free DOX however, appeared to have an adverse effect on the health of the animals over the 28 day 
period and imparted significant toxicity, with their body mass dropping rapidly by the end of the study by 20 % of their 
original mass. This was also the expected result, as it is well known that the toxicity imparted on other healthy cells in 
the body is a major disadvantage of systemically delivered chemotherapeutics.
58, 59
 However, despite the significant 
toxicity to the animals, the DOX was able to partially arrest the tumour growth compared with the HBP control 
treatment, with the tumour volume decreasing by 30 % over the 28 days. This result is commensurate with similar 
studies in the literature, where the free drug was able to have an effect on tumour growth, but to the detriment of the 
overall health of the animals.
50, 60-62
 Additionally, this result aligns with the live cell confocal microscopy results, which 
shed light on the mechanism of uptake of free DOX into the LNCaP tumour cells. The free drug relied on passive 
mechanisms of transport into the cells, and therefore due to the short circulation times that small molecules have 
Figure 8. A) The tumour volumes and body mass of mice expressed as a percentage of the initial value, following a tumour 
regression study over 28 days and B) the excised tumours after the 28 day period. Arrows represent days on which mice were 
dosed (100 µL of 4.5 mg/kg in DOX), blue arrow represents treatment group dosed on day 14. Asterisk represents saline control 
mouse that was culled on day 25 for ethical reasons.  Data represents mean ± SD (n = 2-3 mice). 
Figure 7. Nu/nu mouse with subcutaneous PSMA-expressing tumour on right flank. Fluorescence images were taken 24 hours post 
injection with HBP-GU-DOX showing the location of the tumour (DsRed), the polymer (Cy5) and an overlay of the two signals 
demonstrating co-localisation of the targeted polymer with the PSMA-expressing tumour (black circle). 
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to efficiently be accumulating within the tumour mass.
63
 Importantly, the HBP-GU-DOX was indeed successful in 
imparting a therapeutic effect on the tumours in vivo. As seen in Figure 8A, the body mass of the mice did not vary 
significantly over the experiment, suggesting that the polymer did not lead to significant DOX release during circulation, 
and therefore not imparting non-specific toxicity on the animals. Additionally, the volume of the tumours decreased by 
over 90 % of their original volume over the 28 day period, confirming the ability of the hyperbranched polymer system 
to be successful as a targeted drug delivery carrier. Furthermore, following the final dose at 18 days, the tumours do 
not regrow, but rather continued decreasing in size out to the 28 day time point of the study. This overall result is in 
agreement with the live cell confocal microscopy, which confirmed that the HBP-GU-DOX was able to transport the DOX 
within the cells into vesicles, with significant accumulation and initial DOX release after 2 hours of exposure. As PEG-
based polymers are known to have long circulation times in vivo, through a combination of the EPR effect and active 
targeting it is expected that significant accumulation of the HBP-GU-DOX within the tumour cells will occur. Evidently, 
following uptake into the cells through receptor-mediated internalisation into endosomes, the acidic environment was 
able to facilitate degradation of the hydrazone bond, and subsequent release of the DOX into the cell. It is important to 
note that this effect was only able to be observed with a combination of active targeting and drug loading, as seen by 
the lack of therapeutic effect from the HBP-DOX.  
Conclusions 
In this report we have demonstrated the successful synthesis of hyperbranched polymers with capabilities for 
targeted drug delivery to prostate cancer cells. The HBP system was able to facilitate a high loading efficiency (~90 %) of 
the chemotherapeutic doxorubicin through facile chemistry with hydrazide monomer units in the polymer backbone. 
The HBPs also featured a glutamate urea targeting ligand for PSMA-expressing prostate cancer cells, and an optical dye 
for in vitro and in vivo analysis.  Characterisation through in vitro cell assays and live cell confocal microscopy 
demonstrated the ability of the DOX-loaded polymers to selectively accumulate within endosomes in PSMA-expressing 
LNCaP cells following receptor-mediated internalisation. Once inside the endosomes, the DOX-loaded polymers were 
shown to release the drug to induce a toxic effect, with DOX-loaded polymers demonstrating toxicity similar to that of 
free DOX over a 48 hour period. In comparison, no toxicity was observed in cells receiving the control HBP.  
In order to demonstrate the ability of the HBP system to act as a theranostic, the therapeutic effect of the DOX-
loaded polymers was assessed through a 28 day tumour regression study in mice. The mice received 5 intravenous 
injections of the HBP-GU-DOX over the 28 days, and demonstrated a ~90 % reduction in tumour volume over that time, 
with no significant change in their body mass. In comparison, free DOX only reduced the tumour volume by ~30 %, and 
caused significant toxicity to the mice, with 20 % loss of body mass over the course of the experiment. The controls of 
saline, HBP-GU and untargeted HBP-DOX did not show any therapeutic effect, with the tumour volumes considerably 
increasing over the time period. Importantly, the body mass of the mice did not decrease significantly, demonstrating 
the biocompatibility of the system in vivo. The hyperbranched polymer system demonstrated here therefore shows 
promise in a preclinical model as a theranostic for treating prostate cancer, and should be further explored in more 
clinically relevant models.  
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